Stock Analiz

Nakamoto Inc. NAKA

Medical/Nursing Services · IPO 2024 · data as of November 13, 2026

$5.00Market cap $92M
Open the interactive analysis →

Nakamoto Inc. (NAKA) is a healthcare company listed in the US with a market value of about $92M. In the twelve months to September 30, 2026 it had revenue of $43M and net income of -$249M, a net margin of -581.0%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is value (2/5); the weakest is future growth (0/5).

Key numbers: a P/E of 0.2, a 5-year average ROIC of -114%.

About Nakamoto

Nakamoto is listed in the US and classified in medical/nursing services, IPO year 2024. It was profitable in 0 of the last 3 years in our data.

Score: 0.8 / 5

Value2/5
Future growth0/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%

Valuation

P/E (TTM)0.2
Forward P/E—
P/FCF—
P/S2.1
P/B0.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-25.9%
Shareholder yield0.4%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-33.0%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1014.5%
ROIC (5-yr avg.)-114.3%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 3 years

Fiscal yearTTM202520242023
Revenue$43M$2M$3M$4M
Net income-$249M-$52M-$4M-$2M
Free cash flow—-$24M-$3M-$463909
EPS (diluted)$46.33$-0.26$-0.67$-0.36
Net margin-581.0%-2867.7%-133.0%-42.9%
ROIC—-21.5%-78.9%-242.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 3 analysts is $13.33, 167% above the current price; targets range from $10.00 to $17.00; the consensus rating is “none”; expected EPS is $-21.06 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is Nakamoto’s P/E ratio?

About 0.2, based on the last twelve months of diluted earnings per share.

Does Nakamoto pay a dividend?

Not currently.

Is Nakamoto a good stock to buy?

We do not give buy or sell advice. Nakamoto scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.